Title of article
A Randomized Multicenter Study Comparing a Paclitaxel Drug-Eluting Balloon With a Paclitaxel-Eluting Stent in Small Coronary Vessels: The BELLO (Balloon Elution and Late Loss Optimization) Study
Author/Authors
Latib، نويسنده , , Azeem and Colombo، نويسنده , , Antonio and Castriota، نويسنده , , Fausto and Micari، نويسنده , , Antonio and Cremonesi، نويسنده , , Alberto and De Felice، نويسنده , , Francesco and Marchese، نويسنده , , Alfredo and Tespili، نويسنده , , Maurizio and Presbitero، نويسنده , , Patrizia and Sgueglia، نويسنده , , Gregory A. and Buffoli، نويسنده , , Francesca and Tamburino، نويسنده , , Corrado and Varbella، نويسنده , , Ferdinando and Menozzi، نويسنده , , Alberto، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2012
Pages
8
From page
2473
To page
2480
Abstract
Objectives
m of this study was to evaluate the efficacy of drug-eluting balloons (DEB) compared with paclitaxel-eluting stents (PES) for the reduction of restenosis in small vessels.
ound
ve been shown to be effective in the treatment of coronary in-stent restenosis, but data are limited regarding their efficacy in de novo disease.
s
(Balloon Elution and Late Loss Optimization) is a prospective, multicenter trial that randomized 182 patients with lesions located in small vessels (reference diameter <2.8 mm) to treatment with paclitaxel DEB and provisional bare-metal stenting (n = 90) or PES implantation (n = 92). The primary endpoint was noninferiority of angiographic in-stent (in-balloon) late loss with a delta of 0.25 mm. Secondary endpoints were angiographic restenosis, target lesion revascularization, and major adverse cardiac events (MACE; death, myocardial infarction, target vessel revascularization) at 6 months.
s
ne characteristics were well matched, except for a smaller vessel size in the DEB group (2.15 ± 0.27 mm vs. 2.25 ± 0.24 mm; p = 0.003). The majority (89%) of lesions involved vessels with a diameter <2.5 mm. Bailout stenting was required in 20% of lesions in the DEB group. The primary endpoint of in-stent (in-balloon) late loss was significantly less with DEB compared with PES (0.08 ± 0.38 mm vs. 0.29 ± 0.44 mm; difference −0.21; 95% CI: −0.34 to −0.09; pnoninferiority < 0.001; psuperiority = 0.001). At 6 months, DEB and PES were associated with similar rates of angiographic restenosis (8.9% vs. 14.1%; p = 0.25), target lesion revascularization (4.4% vs. 7.6%; p = 0.37), and MACE (7.8% vs. 13.2%; p = 0.77).
sions
ent of small-vessel disease with a paclitaxel DEB was associated with less angiographic late loss and similar rates of restenosis and revascularization as a PES. (Balloon Elution and Late Loss Optimization [BELLO]; Study NCT01086579)
Keywords
drug-eluting balloon , late loss , Paclitaxel , restenosis , Revascularization , drug-eluting stent
Journal title
JACC (Journal of the American College of Cardiology)
Serial Year
2012
Journal title
JACC (Journal of the American College of Cardiology)
Record number
1755348
Link To Document